MHY553

MHY553 has been studied in 2 papers since 2017: none in people yet, 2 in animals. The research so far is in animals. The newest paper, Nov 13, 2020: “2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin”.

Intervention

2 papers study it9 findingsUpdated

PubChem

See all 2 papers on MHY553

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funder: Pusan National University
  • Animals2

What did studies of MHY553 find?

9

Studies of MHY553 measured 9 outcomes, among them PPARA, pro-inflammatory cytokine expression and MAPK/AP-1 signaling.

PPARA

upin rats1

1 study
  1. MHY553 activates PPARA in rats (aged rat skin and H2O2-induced Hs27 fibroblasts).

    “inhibits inflammatory cytokines through PPARα activation in the skin”

    Animalsaged rat skin and H2O2-induced Hs27 fibroblastsskin

    2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin

    Experimental gerontology

More on PPARA

Pro-inflammatory cytokine expression

downin rats1

1 study
  1. MHY553 decreases pro-inflammatory cytokine expression in rats (aged rats).

    “MHY553 also inhibited the expression of pro-inflammatory cytokines including COX-2, iNOS, IL-1β, and IL-6”

    Animalsaged ratsskin3 mg or 5 mg/kg/day4 weeks

    2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin

    Experimental gerontology

More on Pro-inflammatory cytokine expression

MAPK/AP-1 signaling

downin rats1

1 study
  1. MHY553 inhibits MAPK/AP-1 signaling in rats (aged rats).

    “downregulated mitogen-activated protein kinase (MAPK)/activator protein-1 (AP-1) signaling”

    Animalsaged ratsskin3 mg or 5 mg/kg/day4 weeks

    2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin

    Experimental gerontology

NF-κB signaling

downin rats1

1 study
  1. MHY553 inhibits NF-κB signaling in rats (aged rats).

    “MHY553 suppressed the NF-κB transcription factor”

    Animalsaged ratsskin3 mg or 5 mg/kg/day4 weeks

    2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin

    Experimental gerontology

More on NF-κB signaling

Reactive oxygen species

downin cells1

1 study
  1. MHY553 decreases reactive oxygen species in cells (dose-dependent).

    “MHY553 dose-dependently scavenged ROS and ONOO−”

    Cells

    2,4-Dihydroxyphenyl-benzo[d]thiazole (MHY553), a synthetic PPARα agonist, decreases age-associated inflammatory responses through PPARα activation and RS scavenging in the skin

    Experimental gerontology

More on Reactive oxygen species

Fatty acid β-oxidation

upin rats1

1 study
  1. MHY553 increases fatty acid β-oxidation in rats.

    “increased mRNA levels of its downstream genes related to fatty acid oxidation, including CPT-1A and ACOX1”

    Animals

    Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

    Oncotarget

More on Fatty acid β-oxidation

Inflammation

downin rats1

1 study
  1. MHY553 decreases inflammation in rats.

    “Furthermore, MHY553 significantly suppresses inflammatory mRNA expression in old rats.”

    Animalsliver

    Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

    Oncotarget

More on Inflammation

Body weight

no changein rats1

1 study
  1. MHY553 showed no clear effect on body weight in rats.

    “without changes in body weight and serum levels of liver injury markers.”

    Animals

    Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

    Oncotarget

Hepatic steatosis

downin rats1

1 study
  1. MHY553 decreases hepatic steatosis in rats.

    “When administered orally, MHY553 markedly ameliorated aging-induced hepatic steatosis without changes in body weight and serum levels of liver injury markers.”

    Animalsliver

    Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

    Oncotarget

More on Hepatic steatosis

Latest